US20050119244A1 - Process for preparing cephalosporins with salified intermediate - Google Patents

Process for preparing cephalosporins with salified intermediate Download PDF

Info

Publication number
US20050119244A1
US20050119244A1 US10/821,986 US82198604A US2005119244A1 US 20050119244 A1 US20050119244 A1 US 20050119244A1 US 82198604 A US82198604 A US 82198604A US 2005119244 A1 US2005119244 A1 US 2005119244A1
Authority
US
United States
Prior art keywords
formula
salt
benzathine
solution
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/821,986
Inventor
Riccardo Monguzzi
Antonio Manca
Leonardo Marsili
Maurizio Zenoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ACS Dobfar SpA
Original Assignee
ACS Dobfar SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20032354 external-priority patent/ITMI20032354A1/en
Priority claimed from ITMI20040233 external-priority patent/ITMI20040233A1/en
Application filed by ACS Dobfar SpA filed Critical ACS Dobfar SpA
Assigned to ACS DOBFAR S.P.A. reassignment ACS DOBFAR S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MANCA, ANTONIO, MARSILI, LEONARDO, MONGUZZI, RICCARDO, ZENONI, MAURIZIO
Priority to US10/916,532 priority Critical patent/US7071329B2/en
Publication of US20050119244A1 publication Critical patent/US20050119244A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Definitions

  • cephalosporins of formula (I) characterised by the 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic chain in position 2 of the 7-ACA, and its derivatives of formula (II) are known in which R 2 can have various meanings including CH 2 OCOCH 3 in the case of 7-ACA, the cefotaxime nucleus or in the case of 7-ACT, the ceftriaxone nucleus, or in the case of Furaca, the ceftiofur nucleus.
  • cephalosporins including those having a different meaning of R 1 and R 2 , has been invented and synthesized with its own synthesis method, so that initially there was no common method suitable for producing all cephalosporins having the 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic chain.
  • This compound is reacted with silylated thiourea to provide a compound of formula (I) in which R 1 and R 2 have the aforesaid meanings and which on subsequent hydrolysis gives the compound having the same formula (I) but in which R 1 is H and R 2 is as aforestated: this compound is ceftriaxone.
  • U.S. Pat. No. 6,522,186 hence provides a compound of formula (IV) in which R 3 is trialkylsilyl.
  • R 3 is trialkylsilyl.
  • the corresponding derivative in which R 3 is however H had already been described in U.S. Pat. No. 4,458,072 and obtained as an amorphous product (column 16, line 49) without any indication of the yield, by a laborious process using a precipitating agent such as petroleum ether: this method is certainly unsuitable for industrial use.
  • 6,552,186 says nothing about yields, as the claimed process comprises direct obtaining of the silylated product of formula (IV) and subsequent reaction with silylated thiourea to give silylated ceftriaxone: the final passage to obtain ceftriaxone disodium salt takes place by the known methods, however overall total process yields are not given.
  • the object of the present invention is to provide a process of high efficiency in terms of final product yield and purity, for producing ceftiofur, cefotaxime, ceftriaxone, and cephalosporins generally, characterised by the same general formula (I) in which R 1 is H or Na and R 2 is chosen from the group consisting of H, CH 3 , CH 2 OCH 3 , CH 2 OCOCH 3 , CH ⁇ CH 2 ,
  • a compound of formula (II) in which R 2 has the aforestated meanings is silylated at the carboxyl to give the corresponding trialkylsilyl-ester which is reacted with a compound of formula (III) in which X is Cl or Br and Y is Cl, or O—CH ⁇ N + (CH 3 ) 2 Cl ⁇ to give a cephalosporin of formula (V) in which X and R 2 have the aforestated meanings, and R 3 is trialkylsilyl, which is hydrolyzed at pH 7 ⁇ 7.5 and then treated in a partly aqueous solution with benzathine or a salt thereof, to obtain crystallization of a new cephalosporin of formula (V) where Z is benzathine, in which the carboxyl is salified by the benzathine, this salt being filtered off, washed with water and reacted in a partly aqueous solvent with thiourea, to lead to the formation of
  • a further considerable advantage of the present invention derives from the fact that the cyclization reaction with thiourea, leading to the formation of HCl, finds in benzathine a base able to subtract it from the solution as the hydrochloride insoluble under reaction conditions. In this manner a solution is obtained containing only cephalosporin in acid form of such purity as to enable it to be very easily crystallized as the sodium salt, by adding a sodium salt such as sodium acetate or sodium 2-ethyl-hexanoate.
  • cephalosporins other than ceftiofur, cefotaxime and ceftriaxone having nuclei different from the aforespecified three, but having the same 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic side chain in position 7.
  • the temperature is raised to +20° C. and the mixture agitated for 1 h35 min at 22° C. ⁇ 23° C. until a solution is obtained. It is cooled to ⁇ 35° C. ⁇ 40° C.
  • Solution B is added dropwise to solution A over 15 minutes maintaining the temperature at ⁇ 35° C. ⁇ 40° C. The reaction terminates within 2 hours at ⁇ 35° C. ⁇ 40° C.
  • the mixture On termination of the reaction the mixture is poured into 500 ml of water at 0° C., maintaining the pH at 7.0 ⁇ 7.5 with triethylamine, while maintaining the temperature at 0° C. 200 ml of ethyl acetate are added and the phases are separated at 0° C. ⁇ +5° C. Extraction is again effected at pH 7.0 ⁇ 7.5 with 350 ml of water.
  • the aqueous phase is decolorized at 0° C. ⁇ +5° C. for 30 minutes with 4 g of carbon and 0.4 g of EDTA. It is filtered and washed with 150 ml of water.
  • the pH is adjusted to 7.0 ⁇ 7.5 with triethylamine at 0° C. ⁇ +5° C. using a total of 110 ml thereof.
  • the precipitate is filtered off and washed with 500 ml of water divided into two portions. It is left to drip well.
  • condensation product of 7-FURACA with activated COMBA, precipitated moist as benzathine salt, is used as such in the next passage.
  • a sample is dried for analysis.
  • the temperature is raised to +10° C. ⁇ +15° C. and the pH adjusted to 8.0 ⁇ 8.5 with 15 ml of triethylamine.
  • the impoverished organic phase is re-extracted with a further 400 ml of water at pH 8.08.5, the aqueous phases are pooled and washed with 300 ml of ethyl acetate. 400 ml of tetrahydrofuran are added to the aqueous phase.
  • the mixture is cooled to 0° C. ⁇ +5° C. and the pH adjusted to 3 with 1N hydrochloric acid. 300 g of sodium chloride are added and the mixture agitated until a solution forms, while raising the temperature to +15° C. ⁇ +20° C.
  • the phases are separated, the overlying organic phase being rich in product.
  • Carbon is added to the organic phase at +15° C. ⁇ +20° C. and the mixture agitated for 20 minutes. The mixture is filtered and washed with 100 ml of tetrahydrofuran.
  • a homogeneous mixture of 28.88 g of sodium 2-ethylhexanoate and 100 ml of tetrahydrofuran is added dropwise to the decolorized organic phase over 20 minutes.
  • the mixture is agitated for 15 minutes at +15° C. ⁇ +20° C.
  • the mixture is agitated for 2 hours at +20° C., filtered and washed with 320 ml of acetone.
  • the product is dried at +30° C. ⁇ +32° C. to obtain 51.3 g of sodium ceftiofur.
  • the dried sample of benzathine salt has the following general formula (V), and more specifically has the general formula which provides the following spectra:
  • Solution B is added dropwise to solution A over 15 ⁇ 20 minutes maintaining the temperature at ⁇ 35° ⁇ 40° C. and washing the flask with 15 ml ethyl acetate.
  • the mixture is agitated for 10 minutes at ⁇ 35° ⁇ 40° C. and the reaction goes to completion.
  • the reaction mixture is poured into a mixture of 50 ml water, 320 ml isopropanol and 270 ml of a saturated aqueous solution of sodium bicarbonate pre-cooled to 0° ⁇ +5° C. without exceeding +5° C. It is agitated for 2 hours at 0° ⁇ +5° C.
  • the phases are separated and the underlying aqueous phase is retained.
  • the rich organic phase is washed with 25 ml water, then with a solution of 22 g NaCl in 80 ml water.
  • the aqueous phases are retained each time and pooled, then re-extracted with 40 ml methylene chloride.
  • the organic phases are pooled and the spent aqueous phase is discarded.
  • the former is decolorized under agitation for 15 minutes with 1.5 g carbon, filtered and the filter is washed with 30 ml of methylene chloride.
  • 150 ml of water are added to the decolorized organic phase at 0° ⁇ +5° C. followed by, still at 0° ⁇ +5° C., a solution of 11.21 g anhydrous sodium acetate in 100 ml water pre-cooled to 0° ⁇ +5° C. After 30 minutes the phases are separated allowing the temperature to rise to about +20° C. The poor organic phase is re-extracted with 100 ml of water, facilitating separation with 50 ml of methylene chloride. The aqueous phases are pooled and decolorized at +20° C. for 30 minutes with 1.5 g of carbon, 0.150 g of EDTA and 0.200 g of celite. The mixture is filtered and the filter is washed with 100 ml water.
  • a solution of 15.14 g of benzathine diacetate in 160 ml demineralised water is added over 15 minutes to the decolorized solution at 15° ⁇ 20° C.
  • the mixture is agitated for 30 minutes at 15° ⁇ 20° C., cooled to 0° ⁇ +5° C. and agitated for 1 hour. It is filtered and washed 3 times with 50 ml of water. It is thoroughly squeezed under a nitrogen flow to obtain 28.52 g of the benzathine salt of the condensation product of 7-ACT with COMBA.
  • a sample is dried for analysis.
  • the dried sample of benzathine salt has the general formula (V), and more specifically has the formula which provides the following spectra:
  • the benzathine salt obtained is suspended in 200 ml water and 142 g of the sulfonic resin Resindion UBK 530 in sodium form and 6.38 g of thiourea are added at 20° ⁇ 25° C.
  • the mixture is agitated for 4 hours at 20° ⁇ 25° C., filtered and washed 8 times with 50 ml of water each time and then decolorized for 20 minutes at 15° ⁇ 20° C. with 1.5 g of carbon, 0.150 g of EDTA and 0.200 g of celite.
  • the carbon is filtered off and the filter is washed 4 times with 50 ml water.
  • the pH is adjusted to about 4.2 with 7 ml of 17% hydrochloric acid at 15°/20° C., until precipitation begins. It is agitated for 30 minutes, and adjusted to pH 3 over 40 minutes at 15° ⁇ 20° C. with about 13 ml of 0.17% hydrochloric acid.
  • the initial filtrate is maintained under agitation with 1.33 g carbon, 0.07 g EDTA and 0.13 g celite, for 45 minutes at +10° C. This is filtered off and washed with the mixture of the two washes kept separate from the initial filtrate, the decolorized solution being diluted with 79.5 ml acetone added dropwise over 10 minutes at +10° C. It is seeded with disodium ceftriaxone and agitated for 90 minutes at +10° C. 291.5 ml of acetone are then added dropwise over 3 hours at +10° C. The product is filtered off and washed with 106 ml portions of acetone, thoroughly squeezed under a nitrogen flow then dried at ambient temperature until constant weight, to obtain 22.5 g disodium ceftriaxone.
  • the reaction terminates within about 45 minutes at ⁇ 35° ⁇ 40° C.
  • 600 ml of water at 0° C. are poured in, adjusting the pH to 7 ⁇ 7.5 with triethylamine and maintaining the temperature at 0° ⁇ +5° C.
  • the organic phase is extracted again with 450 ml of water at 0° ⁇ +5° C., maintaining the pH at 7 ⁇ 7.5.
  • aqueous phases are pooled and a solution of 85.05 g of benzathine diacetate in 800 ml of water is added dropwise over 60 minutes, maintaining the temperature at 0° ⁇ +5° C. It is agitated for 1 hour at 0° ⁇ +5° C., the product is filtered off then washed twice with 250 ml water and thoroughly squeezed. 152 g of moist condensation product of 7-ACA with COMBA as the benzathine salt are obtained.
  • a sample is dried for analysis.
  • the dried sample of benzathine salt has the general formula (V) and more specifically has the formula which provides the following spectra:
  • the moist product obtained is suspended in a mixture of 320 ml of tetrahydrofuran and 80 ml of water, cooled to 0° ⁇ 5° C. and 22 ml of triethylamine are added to pH 7.5. 24.84 g of thiourea are added and left to react for 4 hours at +20° ⁇ +25° C. until conversion of the aforestated condensation product to cefotaxime is complete.
  • the temperature is raised to +20° C. and the mixture is agitated for 95 minutes at +22° ⁇ +23° C. until completely dissolved. It is then cooled to ⁇ 35° ⁇ -40° C.
  • Solution B is added dropwise into solution A over 15 minutes, maintaining the temperature at ⁇ 35° ⁇ 40° C. It is left to react for 2 hours at the same temperature.
  • the reaction mixture On termination of the reaction the reaction mixture is poured into 100 ml of iced water, correcting the pH to 3.0 with about 20 ml of triethylamine and maintaining the temperature at 0° ⁇ +5° C. The temperature is raised to +15° ⁇ +20° C. and the phases are separated. The aqueous phase is again extracted with 100 ml of ethyl acetate, the organic phases are pooled and decolorized with 2 g of carbon maintaining agitation for 20 minutes at 15° ⁇ ° C. The latter is filtered off, the filter is washed with 25 ml of tetrahydrofuran and then with 25 ml of ethyl acetate.
  • the solution is cooled to 0 ⁇ +5° C. and 200 ml water at 0 ⁇ +5° C. are added. At the same temperature the pH is corrected to 8 with about 13 ml of triethylamine.
  • the phases are separated and extracted twice more with 100 ml water maintaining the pH at 8 with 3 ml of triethylamine.
  • the aqueous phases are pooled and a solution of benzathine diacetate (27.75 g, MW 360.4) in 262.5 ml water is added dropwise over 30 minutes, at 0° ⁇ +5° C., then the remaining benzathine solution left in the dropping funnel is recovered, washing it with water (37.5 ml). Agitation is maintained for 2 hours at 0° ⁇ +5° C., then the product is filtered off and allowed to well drain, then finally washed 4 times, each time with 50 ml of water. 112 g of intermediary product as moist benzathine salt are obtained, with a K.F. of about 60%.
  • the moist product with the aforestated K.F. is suspended in tetrahydrofuran (250 ml) at +20°25° C. 200 g of UBK530 resin in sodium form and 5.86 g of thiourea are added in the stated order to the suspension obtained, the pH then being corrected to 8.0 ⁇ 8.5 with triethylamine (2.5 ml).
  • Triethylamine (7.5 ml) is added to achieve pH 8.0 ⁇ 8.5 and then ethyl acetate (200 ml). The phases are separated and the aqueous phase is decolorized with 2 g of carbon, adding 0.2 g of EDTA and 0.2 g of celite and agitating for 20 minutes.
  • the organic phase is re-extracted with 100 ml of water, which is used to wash the filter following decolorization, whereas the organic phase is finally removed.
  • 125 ml of tetrahydrofuran are added to the decolorized aqueous phase, cooled to 0° ⁇ +5° C. and the pH corrected to 3 with about 60 ml of 1N HCl. 50 g of sodium chloride are then added at the same temperature, the mixture is heated to +15° ⁇ +20° C. and the phases are separated.
  • the phases are again separated, the organic phase is re-extracted with water (150 ml) at pH 8.0 ⁇ 8.5
  • the aqueous phases are pooled, washed 3 times with ethyl acetate (200 ml each time), the aqueous phase is decolorized with 2 g of carbon +0.2 g EDTA+0.2 g celite.
  • the moist solid is suspended in tetrahydrofuran (125 ml) and agitated at 20° C. until dissolution is virtually complete, after about 30 minutes, then a saturated aqueous solution (50 ml) of sodium chloride is added and further agitated until complete homogenisation of the mixture.
  • the phases are separated.
  • the organic phase is decolorized with 2 g carbon at 20° C., filtered and washed with 50 ml tetrahydrofuran. It is cooled to 0° ⁇ +5° C., the pH is corrected to 0.5 with concentrated HCl (about 5.5 ml) and maintained under agitation for 10 minutes at 0° ⁇ +5° C.
  • the acid solution is added dropwise over 45 minutes to 1500 ml acetone while agitated at 20° C. Agitation is continued for a further 60 minutes at 20° C., then the mixture is cooled to 0°/+5° C. and again agitated for a further 60 minutes.
  • the product is filtered off and washed with 150 ml acetone to obtain 29 g of moist product.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cephalosporins may be conveniently prepared by a process in which 7-ACA is silylated, acylated, desilylated and then salified to give an intermediate which is eventually cyclized with thiourea.

Description

    FIELD OF THE INVENTION
  • Numerous cephalosporins of formula (I)
    Figure US20050119244A1-20050602-C00001
    characterised by the 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic chain in position 2 of the 7-ACA, and its derivatives of formula (II)
    Figure US20050119244A1-20050602-C00002
    are known in which R2 can have various meanings including CH2OCOCH3 in the case of 7-ACA, the cefotaxime nucleus or
    Figure US20050119244A1-20050602-C00003
    in the case of 7-ACT, the ceftriaxone nucleus, or
    Figure US20050119244A1-20050602-C00004
    in the case of Furaca, the ceftiofur nucleus.
    • BACKGROUND OF THE INVENTION
  • Each of these cephalosporins, including those having a different meaning of R1 and R2, has been invented and synthesized with its own synthesis method, so that initially there was no common method suitable for producing all cephalosporins having the 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic chain.
    • DESCRIPTION OF THE RELATED ART
  • Recently, in 1996, U.S. Pat. No. 5,583,216 was granted (the filing date of which however was many years previously), generically covering any process usable for inserting the aforesaid chain into 7-ACA and its derivatives. In this manner, any cephalosporin included in the aforesaid group falls within the scope of protection of U.S. Pat. No. 5,583,216 for what concerns the methods used up to the present time for its production, even if that cephalosporin was invented many years prior to the granting of U.S. Pat. No. 5,583,216: however in truth, this patent does not describe any process which can be applied industrially for producing cephalosporins.
  • To avoid U.S. Pat. No. 5,583,216, considerable research has been carried out, leading inter alia to the granting of U.S. Pat. No. 6,458,949 which claims the intermediate of formula (A)
    Figure US20050119244A1-20050602-C00005
    in which X is Cl or Br, usable for preparing ceftiofur by cyclization with thiourea.
  • This intermediate is always precipitated in acid form from a solution in methylene chloride at 2-5° C., filtered off, washed with cold water (5° C.) and then with methylene chloride. In fact, considering that the precipitate originates from a solution in methylene chloride, according to the usual technique it would have been logical to expect the first wash to have been effected with the same solvent, the water wash being effected only later. This reversal of the wash order and the use of cold water is therefore not random, but points to the fact that the intermediate does not possess great stability and that the water-soluble acid impurities which impregnate the solid just filtered off must be rapidly removed. In addition the intermediate claimed in U.S. Pat. No. 6,458,949, again in acid form, is dried before subsequent cyclization with thiourea, as this reaction is carried out in water-tetrahydrofuran and it is advisable to remove methylene chloride residues. Moreover the maximum obtainable yield is only 75%. U.S. Pat. No. 6,552,186 claims a compound of formula (IV)
    Figure US20050119244A1-20050602-C00006
    in which X is halogen, R3 is trialkylsilyl and R2 is
    Figure US20050119244A1-20050602-C00007
  • This compound is reacted with silylated thiourea to provide a compound of formula (I) in which R1 and R2 have the aforesaid meanings and which on subsequent hydrolysis gives the compound having the same formula (I) but in which R1 is H and R2 is as aforestated: this compound is ceftriaxone.
  • U.S. Pat. No. 6,522,186 hence provides a compound of formula (IV) in which R3 is trialkylsilyl. The corresponding derivative in which R3 is however H had already been described in U.S. Pat. No. 4,458,072 and obtained as an amorphous product (column 16, line 49) without any indication of the yield, by a laborious process using a precipitating agent such as petroleum ether: this method is certainly unsuitable for industrial use. Again, U.S. Pat. No. 6,552,186 says nothing about yields, as the claimed process comprises direct obtaining of the silylated product of formula (IV) and subsequent reaction with silylated thiourea to give silylated ceftriaxone: the final passage to obtain ceftriaxone disodium salt takes place by the known methods, however overall total process yields are not given.
  • The recent U.S. Pat. No. 6,458,949 claims a process by which Furaca is silylated and then reacted with a compound of formula (III)
    Figure US20050119244A1-20050602-C00008
    in which X is Cl or Br and Y is Cl, or
    O—CH═N+(CH3)2Cl−
      • to isolate an aforestated compound of formula (A), in which X is Cl or Br and the carboxyl is free, non-salified and non-esterified.
  • When reacted with thiourea in a partly aqueous solvent, this intermediate produces ceftiofur.
  • Compounds of formula (III) have been known for some time: for example, GB 2,012,276 describes in example 5 the preparation of a compound of formula (III) in which the methoxyimino group is substituted by the ethoxyimino group, X is Br and Y is Cl, by reacting the corresponding acid having the same formula (III) but in which X is Br and Y is OH, with PCl5 in a dichloromethane solution. According to example 13 of the patent, 7-(4-chloro-3-oxo-2-methoxyiminobutyryl-amino)cephalosporanic acid is subsequently reacted with thiourea to give a sodium salt of 7-[2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido)cephalosporanic acid, this being cefotaxime, EP 30294 (page 4, lines 36-37 and 40-45), U.S. Pat. No. 6,384,215 (column 3, lines 19-20) and U.S. Pat. No. 6,458,949 (column 4, line 1; column 5, line 2 and lines 47-48) also describe the preparation of compounds of formula similar to formula (III).
  • It is therefore apparent that compounds of formula (III) in activated form, able to react with a compound of formula (II) silylated at the carboxyl, can be prepared for example as chlorides by reaction with PCl5 or other chlorinating agents, such as POCl3 and DMF, in dichloromethane.
    • SUMMARY OF THE INVENTION
  • The object of the present invention is to provide a process of high efficiency in terms of final product yield and purity, for producing ceftiofur, cefotaxime, ceftriaxone, and cephalosporins generally, characterised by the same general formula (I)
    Figure US20050119244A1-20050602-C00009
    in which R1 is H or Na and R2 is chosen from the group consisting of H, CH3, CH2OCH3, CH2OCOCH3, CH═CH2,
    Figure US20050119244A1-20050602-C00010
  • According to this process, a compound of formula (II)
    Figure US20050119244A1-20050602-C00011
    in which R2 has the aforestated meanings is silylated at the carboxyl to give the corresponding trialkylsilyl-ester which is reacted with a compound of formula (III)
    Figure US20050119244A1-20050602-C00012
    in which X is Cl or Br and Y is Cl, or
    O—CH═N+(CH3)2 Cl−
    to give a cephalosporin of formula (V)
    Figure US20050119244A1-20050602-C00013
    in which X and R2 have the aforestated meanings, and R3 is trialkylsilyl, which is hydrolyzed at pH 7÷7.5 and then treated in a partly aqueous solution with benzathine or a salt thereof, to obtain crystallization of a new cephalosporin of formula (V)
    Figure US20050119244A1-20050602-C00014
    where Z is benzathine, in which the carboxyl is salified by the benzathine, this salt being filtered off, washed with water and reacted in a partly aqueous solvent with thiourea, to lead to the formation of the 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic chain and give a solution of the compound of general formula (I) in which R2 has the aforestated meanings and R1 is H, the compound of formula (I) being crystallized from this solution in the form of the sodium salt, of the salt of a pharmaceutically acceptable inorganic acid or of an internal salt.
  • Simultaneously with the formation of the 2-(2-aminothiazol-4-yl)-2-methoxyyminoacetic chain there may be the precipitation of benzathine hydrochloride which is filtered off and removed to leave a very pure solution of the compound of general formula (I).
  • In particular, it has been surprisingly found possible to quantitatively isolate in aqueous solution a cephalosporin of formula (V), in which R2 is CH2OCOCH3, or
    Figure US20050119244A1-20050602-C00015
    without any interaction with the halogen atom X present in the compounds of formula (V).
  • This precipitation, in aqueous solution automatically eliminates all the acid impurities originating from the preparation of the aforesaid compounds of formula (V), then by simply washing with water a high purity moist product is obtained ready for subsequent reaction with thiourea in a partly aqueous environment.
  • A further considerable advantage of the present invention derives from the fact that the cyclization reaction with thiourea, leading to the formation of HCl, finds in benzathine a base able to subtract it from the solution as the hydrochloride insoluble under reaction conditions. In this manner a solution is obtained containing only cephalosporin in acid form of such purity as to enable it to be very easily crystallized as the sodium salt, by adding a sodium salt such as sodium acetate or sodium 2-ethyl-hexanoate.
  • This succession of operations will be more apparent from the non-limiting examples which follow.
  • However, the same operative scheme can evidently be applied for the production of cephalosporins other than ceftiofur, cefotaxime and ceftriaxone, having nuclei different from the aforespecified three, but having the same 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic side chain in position 7.
    • DETAILED DESCRIPTION OF THE INVENTION EXAMPLE 1 Preparation of Sodium Ceftiofur
  • Two separate solutions are prepared.
  • Solution A
  • 40 g of FURACA (MW 340.38-0.118 moles) and 336 ml of tetrahydrofuran are fed into a dry 1 litre flask under a nitrogen flow in the absence of direct light. The mixture is agitated for 15 minutes until homogenization, while cooling in the meantime to +10° C.
  • While maintaining the temperature at +10° C.÷+12° C., 1.486 ml of trimethylchlorosilane (MW 108.64-d=0.859-0.1 eq) are quickly added. The mixture is agitated for 5 min at +10° C.÷+12° C., and 45.43 g of N,O-bis-trimethylsilyl-acetamide (MW 203.43-d=0.832-1.9 eq) are added over 5÷10 minutes.
  • The temperature is raised to +20° C. and the mixture agitated for 1 h35 min at 22° C.÷23° C. until a solution is obtained. It is cooled to −35° C.÷−40° C.
  • Solution B
  • 210 ml of ethyl acetate and 13.02 ml of N,N-dimethylformamide (MW 73.094-0.169 moles-d=0.95-12.37 g) are fed into a dry 1 litre flask under a nitrogen flow.
  • 15.49 ml of phosphorus oxychloride (POCl3) (0.167 moles-MW 153.33-d=1.675-25.95 g) are added at +25° C., allowing the temperature to rise to +36° C.
  • The mixture is cooled to 0° C. and 27.62 g of 4-chloro-3-oxo-2-methoxyimino-butyric acid, commonly known as COMBA (MW 179.56-0.154 moles) are added without exceeding +5° C. The mixture is agitated for 1 hour at +5° C.
  • Solution B is added dropwise to solution A over 15 minutes maintaining the temperature at −35° C.÷−40° C. The reaction terminates within 2 hours at −35° C.÷−40° C.
  • On termination of the reaction the mixture is poured into 500 ml of water at 0° C., maintaining the pH at 7.0÷7.5 with triethylamine, while maintaining the temperature at 0° C. 200 ml of ethyl acetate are added and the phases are separated at 0° C. ÷+5° C. Extraction is again effected at pH 7.0÷7.5 with 350 ml of water.
  • The aqueous phase is decolorized at 0° C.÷+5° C. for 30 minutes with 4 g of carbon and 0.4 g of EDTA. It is filtered and washed with 150 ml of water.
  • The pH is adjusted to 7.0÷7.5 with triethylamine at 0° C.÷+5° C. using a total of 110 ml thereof.
  • A mixture of 43.25 g of benzathine diacetate (0.120 moles) dissolved in 350 ml of water is added dropwise, then washing with 50 ml of water.
  • It is left to precipitate cold at 0° C.÷+5° C. for about 90 minutes.
  • The precipitate is filtered off and washed with 500 ml of water divided into two portions. It is left to drip well.
  • The condensation product of 7-FURACA with activated COMBA, precipitated moist as benzathine salt, is used as such in the next passage.
  • A sample is dried for analysis.
  • The moist benzathine salt obtained as described is suspended in 740 ml of tetrahydrofuran at +20° C.÷+25° C.
  • It is cooled to 0° C.÷+5° C. and 19 ml of triethylamine are added, maintaining this temperature. 12 g of thiourea are added at 0° C.÷+25° C. and the mixture agitated for 18 hours.
  • It is cooled to 0° C.÷+5° C. and, while maintaining this temperature, 600 ml of ethyl acetate are added plus about 20 ml of concentrated hydrochloric acid to pH 3. The precipitated benzathine hydrochloride is filtered off and the filter washed with a mixture of 60 ml of tetrahydrofuran +60 ml of ethyl acetate.
  • 400 ml of water are added to the filtrate solution.
  • The temperature is raised to +10° C.÷+15° C. and the pH adjusted to 8.0÷8.5 with 15 ml of triethylamine.
  • The phases are separated.
  • The impoverished organic phase is re-extracted with a further 400 ml of water at pH 8.08.5, the aqueous phases are pooled and washed with 300 ml of ethyl acetate. 400 ml of tetrahydrofuran are added to the aqueous phase.
  • The mixture is cooled to 0° C.÷+5° C. and the pH adjusted to 3 with 1N hydrochloric acid. 300 g of sodium chloride are added and the mixture agitated until a solution forms, while raising the temperature to +15° C.÷+20° C.
  • The phases are separated, the overlying organic phase being rich in product. Carbon is added to the organic phase at +15° C.÷+20° C. and the mixture agitated for 20 minutes. The mixture is filtered and washed with 100 ml of tetrahydrofuran.
  • A homogeneous mixture of 28.88 g of sodium 2-ethylhexanoate and 100 ml of tetrahydrofuran is added dropwise to the decolorized organic phase over 20 minutes.
  • The mixture is agitated for 15 minutes at +15° C.÷+20° C.
  • The solution obtained is added dropwise over 30 minutes to 1000 ml of agitated tetrahydrofuran at +20° C.
  • The mixture is agitated for 2 hours at +20° C., filtered and washed with 320 ml of acetone.
  • The product is dried at +30° C.÷+32° C. to obtain 51.3 g of sodium ceftiofur.
  • The dried sample of benzathine salt has the following general formula (V), and more specifically has the general formula
    Figure US20050119244A1-20050602-C00016
    which provides the following spectra:
  • 1HNMR in DMSO-d6 300 Mhz; Hc=9.40 ppm 1H; Hn=8.04 ppm 1H; Hu-Hv=7.32-7.46 ppm 10H; Hl=7.39 ppm 1H; Hm=6.77 ppm 1H; Hd=5.68 ppm 1H; He=5.06 ppm 1H; Hq-Hr=4.84 ppm 3H; Hb=3.95 ppm 3H; Hh-Hi=4.22-3.99 ppm 2H; Hf-Hg=3.65-3.26 ppm 2H; Hs-Ht=4.03 ppm 4H; Ho-Hp=2.95 ppm 4H; Ha=3.97 ppm 2H.
  • FT-IR (cm1); 1777.6-1717.1-1650.7-1565.8
    • EXAMPLE 2 Preparation of Ceftriaxone Disodium Salt
  • Two separate solutions are prepared.
  • Solution A
  • 15.57 g of 7-ACT (MW 371.39-0.042 mol) and 155 ml of methylene chloride are fed into a dry 1 litre flask under a nitrogen flow in the absence of direct light. The mixture is cooled to +10° C. and 34.11 g of N,O-bis-trimethylsilyl-acetamide are added, a slight amount of heat being produced. The mixture is agitated at +20÷22° C. and after 45 minutes a complete solution is obtained. The mixture is cooled to −40° C.
  • Solution B
  • 80 ml of ethyl acetate and 4.69 ml of N,N-dimethylformamide (MW 73.09, d=0.95) are fed into a dry 1 litre flask under a nitrogen flow at +25° C. 5.58 ml of phosphorus oxychloride (MW 153.33, d=1.675, 9.34 g) are added allowing the temperature to rise to 36° C. (if this temperature is not attained within 20÷25 minutes, heating is required). The mixture is cooled to 0° C. then 9.94 g of 4-chloro-3-oxo-2-methoxyimino-butyric acid, commonly known as COMBA (MW 179.56) are added. The mixture is agitated at +5° C. for 1 hour. Solution B is added dropwise to solution A over 15÷20 minutes maintaining the temperature at −35°÷−40° C. and washing the flask with 15 ml ethyl acetate. The mixture is agitated for 10 minutes at −35°÷−40° C. and the reaction goes to completion. The reaction mixture is poured into a mixture of 50 ml water, 320 ml isopropanol and 270 ml of a saturated aqueous solution of sodium bicarbonate pre-cooled to 0°÷+5° C. without exceeding +5° C. It is agitated for 2 hours at 0°÷+5° C. maintaining the pH at 2.5 (consuming about 27 ml of 17% hydrochloric acid), the pH being checked for about 90 minutes, during which any necessary correction is done with solid sodium bicarbonate. The phases are separated and the underlying aqueous phase is retained. The rich organic phase is washed with 25 ml water, then with a solution of 22 g NaCl in 80 ml water. The aqueous phases are retained each time and pooled, then re-extracted with 40 ml methylene chloride. The organic phases are pooled and the spent aqueous phase is discarded. The former is decolorized under agitation for 15 minutes with 1.5 g carbon, filtered and the filter is washed with 30 ml of methylene chloride. 150 ml of water are added to the decolorized organic phase at 0°÷+5° C. followed by, still at 0°÷+5° C., a solution of 11.21 g anhydrous sodium acetate in 100 ml water pre-cooled to 0°÷+5° C. After 30 minutes the phases are separated allowing the temperature to rise to about +20° C. The poor organic phase is re-extracted with 100 ml of water, facilitating separation with 50 ml of methylene chloride. The aqueous phases are pooled and decolorized at +20° C. for 30 minutes with 1.5 g of carbon, 0.150 g of EDTA and 0.200 g of celite. The mixture is filtered and the filter is washed with 100 ml water.
  • A solution of 15.14 g of benzathine diacetate in 160 ml demineralised water is added over 15 minutes to the decolorized solution at 15°÷20° C. The mixture is agitated for 30 minutes at 15°÷20° C., cooled to 0°÷+5° C. and agitated for 1 hour. It is filtered and washed 3 times with 50 ml of water. It is thoroughly squeezed under a nitrogen flow to obtain 28.52 g of the benzathine salt of the condensation product of 7-ACT with COMBA. A sample is dried for analysis.
  • The dried sample of benzathine salt has the general formula (V), and more specifically has the formula
    Figure US20050119244A1-20050602-C00017
    which provides the following spectra:
  • 1HNMR in DMSO-d6 300 MHz: Hc=9.36 ppm 1H; Hu-Hv=7.30-7.42 ppm 10H; Hd=5.65 ppm 1H; He=5.03 ppm 1H; Ha-Ha′=4.84 ppm 3H; Hb=4.03 ppm 3H; Hq-Hr=3.91 ppm 3H; Hh-Hi=4.35-4.12 ppm 2H; Hm=3.50 ppm 3H; Hf-Hg=3.62-3.39 ppm 2H; Hs-Ht=3.53 ppm 4H; Ho-Hp=2.89 ppm4H.
  • FT-IR (cm−1): 1775.1-1715.7-1666.6-1594.1
  • The benzathine salt obtained is suspended in 200 ml water and 142 g of the sulfonic resin Resindion UBK 530 in sodium form and 6.38 g of thiourea are added at 20°÷25° C. The mixture is agitated for 4 hours at 20°÷25° C., filtered and washed 8 times with 50 ml of water each time and then decolorized for 20 minutes at 15°÷20° C. with 1.5 g of carbon, 0.150 g of EDTA and 0.200 g of celite. The carbon is filtered off and the filter is washed 4 times with 50 ml water. The pH is adjusted to about 4.2 with 7 ml of 17% hydrochloric acid at 15°/20° C., until precipitation begins. It is agitated for 30 minutes, and adjusted to pH 3 over 40 minutes at 15°÷20° C. with about 13 ml of 0.17% hydrochloric acid.
  • It is filtered off, washed twice with 50 ml water and thoroughly squeezed to obtain 45 g of crude ceftriaxone acid (K.F.=about 60%).
  • 79.5 ml of acetone, 20 ml of water, 80 g of carboxylic resin RELITE CNS (activated in sodium form) are fed into a flask. The mixture is cooled to +10° C. and 45 g of well-sifted crude ceftriaxone acid obtained above are added, then agitated at +10° C. for 4 hours until the dissolved ceftriaxone content remains constant. The resin is filtered off, washed with a mixture of 10 ml water+8 ml acetone and then with a mixture of 6 ml water and 19 ml acetone, maintaining these washes separate from the initial filtrate and at +10° C. The initial filtrate is maintained under agitation with 1.33 g carbon, 0.07 g EDTA and 0.13 g celite, for 45 minutes at +10° C. This is filtered off and washed with the mixture of the two washes kept separate from the initial filtrate, the decolorized solution being diluted with 79.5 ml acetone added dropwise over 10 minutes at +10° C. It is seeded with disodium ceftriaxone and agitated for 90 minutes at +10° C. 291.5 ml of acetone are then added dropwise over 3 hours at +10° C. The product is filtered off and washed with 106 ml portions of acetone, thoroughly squeezed under a nitrogen flow then dried at ambient temperature until constant weight, to obtain 22.5 g disodium ceftriaxone.
    • EXAMPLE 3 Preparation of Cefotaxime Sodium Salt
  • Two separate solutions are firstly prepared.
  • Solution A
  • 64 g of 7-ACA (MW 272.28-0.235 mol) and 400 ml of tetrahydrofuran are fed into a dry 1 litre flask under a nitrogen flow and in the absence of direct light. The mixture is agitated for 15 minutes until homogenized while cooling to +15° C.
  • 191.34 g of N,O-bis-trimethylsilyl-acetamide (MW 203.43, d=0.832, 0.941 mol) are quickly added, maintaining the temperature at 20°÷25° C. The temperature is maintained at 20°÷25° C. while the mixture is agitated for 15 minutes at +20°÷+25° C. until dissolved, then cooled to −35° C.÷−40° C.
  • Solution B
  • 420 ml of ethyl acetate and 26.04 ml of N,N-dimethylformamide (MW 73.09, d=0.95, 0.338 mol, 24.74 g) are fed into a dry 1 litre flask under a nitrogen flow at +25° C. 30.98 ml of phosphorus oxychloride (MW 153.33, d=1.675, 51.9 g) are added allowing the temperature to rise to 36° C. (if this temperature is not attained in 20÷25 minutes, heating is required). The mixture is cooled to 0° C. then, without exceeding +5° C., 55.24 g of 4-chloro-3-oxo-2-methoxyimino-butyric acid, commonly known as COMBA (MW 179.56-0.308 mol) are added. The mixture is agitated at +5° C. for 1 hour. Solution B is added dropwise into solution A over 15÷20 minutes while maintaining the temperature at −35°÷−40° C.
  • The reaction terminates within about 45 minutes at −35°÷−40° C. At the end of the reaction 600 ml of water at 0° C. are poured in, adjusting the pH to 7÷7.5 with triethylamine and maintaining the temperature at 0°÷+5° C.
  • The organic phase is extracted again with 450 ml of water at 0°÷+5° C., maintaining the pH at 7÷7.5.
  • The aqueous phases are pooled and a solution of 85.05 g of benzathine diacetate in 800 ml of water is added dropwise over 60 minutes, maintaining the temperature at 0°÷+5° C. It is agitated for 1 hour at 0°÷+5° C., the product is filtered off then washed twice with 250 ml water and thoroughly squeezed. 152 g of moist condensation product of 7-ACA with COMBA as the benzathine salt are obtained.
  • A sample is dried for analysis.
  • The dried sample of benzathine salt has the general formula (V) and more specifically has the formula
    Figure US20050119244A1-20050602-C00018
    which provides the following spectra:
  • 1HNMR in DMSO-d6 300 MHz: Hc=9.42 ppm 1H; Hu-Hv=7.36-7.46 ppm 10H; Hd=5.73 ppm 1H; He=5.03 ppm 1H; Hq-Hr=4.85 ppm 3H; Hb=3.95 ppm 3H; Hh-Hi=4.11-4.03 ppm 2H;
  • Hf-Hg=3.55-3.36 ppm 2H; Hs-Ht=3.99 ppm 4H; Ho-Hp=3.05 ppm 4H; Ha=2.03 ppm 2H.
  • FT-IR (cm−1): 1766.3-1719.5-1660.0-1555.8
  • The moist product obtained is suspended in a mixture of 320 ml of tetrahydrofuran and 80 ml of water, cooled to 0°÷−5° C. and 22 ml of triethylamine are added to pH 7.5. 24.84 g of thiourea are added and left to react for 4 hours at +20°÷+25° C. until conversion of the aforestated condensation product to cefotaxime is complete.
  • On termination of the reaction 1.6 g of sodium hydrosulfite, 0.4 g of EDTA, 0.8 g of celite and 4 g of carbon are added and the mixture is agitated for 20 minutes then filtered, washing the product with 80 ml of tetrahydrofuran. The tetrahydrofuran is evaporated under reduced pressure until an oily residue forms. 368 ml of water are added dropwise to the oil obtained under agitation.
  • 233.6 g of 99% formic acid are dropped over a period of 5÷10 minutes at +15°÷+20° C. into the suspension obtained.
  • It is cooled to 0°÷+5° C. and agitated for 3 hours, filtered and the product washed with 96 ml of water pre-cooled to 0°÷+5° C. The product is suspended in 384 ml of ethanol at 45÷50° C. and agitated for 1 hour. It is filtered off while hot then washed with 192 ml of ethyl acetate.
  • After drying, 36 g of cefotaxime ethanol solvate with a concentration of 85% is obtained, serving as intermediate.
  • 227.5 ml of methanol, 28.2 ml of water and 32.8 g of sodium 2-ethylhexanoate are fed into a flask under a nitrogen flow. The mixture is agitated at ambient temperature until completely dissolved and cooled to 0°÷+5° C. The intermediate cefotaxime acid ethanol solvate (87.5 g) is added and complete dissolution is achieved at 0°÷+5° C. The temperature is maintained and 350 ml of ethyl acetate are added over 1 hour. The solution is seeded with cefotaxime sodium salt and agitated for 1 hour at 0°÷+5° C. A further 263 ml of ethyl acetate are added over 40 minutes, then a further 875 ml of ethyl acetate over 1 hour at 0°÷5° C. The mixture is agitated for 30 minutes at the same temperature, filtered and the product washed with 88 ml ethyl acetate and dried at 30° C. under reduced pressure. Yield: 80.5 g of cefotaxime sodium salt.
    • EXAMPLE 4 Preparation Of Ceftiofur Hydrochloride
  • Two separate solutions are prepared.
  • Solution A
  • 20 g of Furaca (MW 340.38-58.76 mmol) and 168 ml of tetrahydrofuran are fed into a dry 1 litre flask under a nitrogen flow and in the absence of direct light. The mixture is agitated for 15 minutes until homogenized while cooling to +10° C. At +10°÷+12° C. 0.743 ml of trimethylchlorosilane (MW 108.64-d=0.859) are quickly added. The mixture is agitated for 5 minutes at +10°÷+12° C. and then 22.72 g BSA (MW=203.43) are added over 5÷10 minutes.
  • The temperature is raised to +20° C. and the mixture is agitated for 95 minutes at +22°÷+23° C. until completely dissolved. It is then cooled to −35°÷−-40° C.
  • Solution B
  • 105 ml of ethyl acetate and 6.51 ml of dimethylformamide (PM 73.09, d=0.95) are fed into a dry 1 litre flask under a nitrogen flow. At +25° C. 7.75 ml of POCl3 (MW 153.33, d=1.675) are added, allowing the temperature to rise to +36° C. over 20÷25 minutes, if necessary heating it slightly. The mixture is cooled to 0° C. and then 13.81 g of 4-chloro-3-oxo-2-methoxyimino-butyric acid, commonly known as COMBA (MW 179.56) are added taking care not to exceed +5° C. Agitation is maintained at +5° C. for 60 minutes.
  • Solution B is added dropwise into solution A over 15 minutes, maintaining the temperature at −35°÷−40° C. It is left to react for 2 hours at the same temperature.
  • On termination of the reaction the reaction mixture is poured into 100 ml of iced water, correcting the pH to 3.0 with about 20 ml of triethylamine and maintaining the temperature at 0°÷+5° C. The temperature is raised to +15°÷+20° C. and the phases are separated. The aqueous phase is again extracted with 100 ml of ethyl acetate, the organic phases are pooled and decolorized with 2 g of carbon maintaining agitation for 20 minutes at 15°÷° C. The latter is filtered off, the filter is washed with 25 ml of tetrahydrofuran and then with 25 ml of ethyl acetate.
  • The solution is cooled to 0÷+5° C. and 200 ml water at 0÷+5° C. are added. At the same temperature the pH is corrected to 8 with about 13 ml of triethylamine.
  • The phases are separated and extracted twice more with 100 ml water maintaining the pH at 8 with 3 ml of triethylamine. The aqueous phases are pooled and a solution of benzathine diacetate (27.75 g, MW 360.4) in 262.5 ml water is added dropwise over 30 minutes, at 0°÷+5° C., then the remaining benzathine solution left in the dropping funnel is recovered, washing it with water (37.5 ml). Agitation is maintained for 2 hours at 0°÷+5° C., then the product is filtered off and allowed to well drain, then finally washed 4 times, each time with 50 ml of water. 112 g of intermediary product as moist benzathine salt are obtained, with a K.F. of about 60%.
  • The moist product with the aforestated K.F., is suspended in tetrahydrofuran (250 ml) at +20°25° C. 200 g of UBK530 resin in sodium form and 5.86 g of thiourea are added in the stated order to the suspension obtained, the pH then being corrected to 8.0÷8.5 with triethylamine (2.5 ml).
  • Agitation is maintained for 3 hours at 20°÷25° C., then further triethylamine (3.5 ml) is added to correct the pH to 7.5÷8.0. After further agitation for 20 hours at 20°÷25° C., a final reaction pH of 2.5÷3.0 is achieved. The resin is filtered off and washed with 2×50 ml portions of tetrahydrofuran, then twice with a mixture of 25 ml tetrahydrofuran+25 ml of ethyl acetate and finally with 25 ml of water.
  • Triethylamine (7.5 ml) is added to achieve pH 8.0÷8.5 and then ethyl acetate (200 ml). The phases are separated and the aqueous phase is decolorized with 2 g of carbon, adding 0.2 g of EDTA and 0.2 g of celite and agitating for 20 minutes.
  • The organic phase is re-extracted with 100 ml of water, which is used to wash the filter following decolorization, whereas the organic phase is finally removed.
  • 125 ml of tetrahydrofuran are added to the decolorized aqueous phase, cooled to 0°÷+5° C. and the pH corrected to 3 with about 60 ml of 1N HCl. 50 g of sodium chloride are then added at the same temperature, the mixture is heated to +15°÷+20° C. and the phases are separated.
  • Water (250 ml) is added to the organic phase and the pH is adjusted to 8.0÷8.5 with triethylamine (about 12.5 ml), then ethyl acetate (250 ml) is added.
  • The phases are again separated, the organic phase is re-extracted with water (150 ml) at pH 8.0÷8.5 The aqueous phases are pooled, washed 3 times with ethyl acetate (200 ml each time), the aqueous phase is decolorized with 2 g of carbon +0.2 g EDTA+0.2 g celite.
  • This is filtered off and washed with water (100 ml), the solution is cooled to 0°÷+5° C. and the pH is adjusted to 3 with about 48 ml of 1N HCl. It is agitated while cold for 1 hour, the product is filtered off and washed twice with 100 ml water. It is left to drip well under nitrogen, to obtain 114 g of moist product.
  • The moist solid is suspended in tetrahydrofuran (125 ml) and agitated at 20° C. until dissolution is virtually complete, after about 30 minutes, then a saturated aqueous solution (50 ml) of sodium chloride is added and further agitated until complete homogenisation of the mixture.
  • The phases are separated. The organic phase is decolorized with 2 g carbon at 20° C., filtered and washed with 50 ml tetrahydrofuran. It is cooled to 0°÷+5° C., the pH is corrected to 0.5 with concentrated HCl (about 5.5 ml) and maintained under agitation for 10 minutes at 0°÷+5° C.
  • The acid solution is added dropwise over 45 minutes to 1500 ml acetone while agitated at 20° C. Agitation is continued for a further 60 minutes at 20° C., then the mixture is cooled to 0°/+5° C. and again agitated for a further 60 minutes. The product is filtered off and washed with 150 ml acetone to obtain 29 g of moist product.
  • It is dried at 20° C. to obtain 20.5 g of ceftiofur hydrochloride.
    Figure US20050119244A1-20050602-C00019
    Ceftiofur Hydrochloride 1HNMR
    • 9.79 ppm doublet Jcd=8.1 Hz Hc
    • 8.06 ppm Hn ddd system abc
    • 7.44 ppm Hm ddd system abc
    • 6.91 ppm Hl ddd system abc
    • 6.76 ppm singlet Ha
    • 5.76 ppm Hd dd Jcd=8.1, Jde=5.16 Hz
    • 5.16 ppm He doublet Jde=5.16 Hz
    • 4.27 ppm, 3.93 ppm Hh, Hi system ab two doublets Jhi=13.2 Hz
    • 3.74 ppm, 3.38 ppm Hf, Hg two doublets system ab
    • Jfg=17.6 Hz
    • 3.92 ppm Hb singlet
      Ceftiofur Hydrochloride FT-IR
    • amide NH stretching 3273 cm−1
    • lactam C═O 1766.3 cm−1
    • thioester C═O 1709.0 cm−1
    • carboxyl C═O 1659.4 cm−1
    • amide C═O 1629.4 cm−1

Claims (6)

1. A process for preparing a cephalosporin of formula (I)
Figure US20050119244A1-20050602-C00020
in which R1 is H or Na and R2 is chosen from the group consisting of H, CH3, CH2OCH3, CH2OCOCH3, CH═CH2,
Figure US20050119244A1-20050602-C00021
according to which a compound of formula (II)
Figure US20050119244A1-20050602-C00022
in which R2 has the aforestated meanings is silylated at the carboxyl to give the corresponding trialkylsilyl-ester which is reacted with a compound of formula (III)
Figure US20050119244A1-20050602-C00023
in which X is Cl or Br and Y is Cl, or

O—CH═N+(CH3)2 Cl−
to give a cephalosporin of formula (IV)
Figure US20050119244A1-20050602-C00024
in which X and R2 have the aforestated meanings, and R3 is trialkylsilyl, which is hydrolyzed at pH 7÷7.5 and then treated in a partly aqueous solution with benzathine or a salt thereof, to obtain crystallization of a new cephalosporin of formula (V)
Figure US20050119244A1-20050602-C00025
where Z is benzathine, in which the carboxyl is salified by the benzathine, this salt being filtered off, washed with water and reacted in a partly aqueous solvent with thiourea, to lead to the formation of the 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic chain and give a solution of the compound of general formula (I) in which R2 has the aforestated meanings and R1 is H, the compound of formula (I) being crystallized from this solution in the form of the sodium salt, of the salt of a pharmaceutically acceptable inorganic acid or of an internal salt.
2. A process according to claim 1, wherein simultaneously with the formation of the 2-(2-aminothiazol-4-yl)-2-methoxyyminoacetic chain, there is the precipitation of benzathine hydrochloride which is filtered off and removed to leave a very pure solution of the compound of general formula (I).
3. A process as claimed in claim 1, wherein a product of formula (I) is obtained in which R1 is H or Na and R2 is chosen from the group consisting of H, CH3, CH2OCH3, CH2OCOCH3, CH═CH2
Figure US20050119244A1-20050602-C00026
4. A process as claimed in claim 2, wherein a product of formula (I) is obtained in which R1 is H or Na and R2 is chosen from the group consisting of H, CH3, CH2OCH3, CH2OCOCH3, CH═CH2
Figure US20050119244A1-20050602-C00027
5. The benzathine salt of a cephalosporin of formula (V)
Figure US20050119244A1-20050602-C00028
where Z, X and R are as specified in claim 1.
6. A process for preparing the benzathine salt of a cephalosporin of formula (V) of claim 5, according to which a compound of formula (II)
Figure US20050119244A1-20050602-C00029
in which R2 has the aforestated meanings, is silylated at the carboxyl to give the corresponding trialkylsilyl-ester which is reacted with a compound of formula (III)
Figure US20050119244A1-20050602-C00030
in which X is Cl or Br and Y is Cl, or

O—CH═N+(CH3)2 Cl−
to give a cephalosporin of formula (IV)
Figure US20050119244A1-20050602-C00031
in which X and R2 are as specified in claim 1, and R3 is trialkylsilyl, which is hydrolyzed at pH 7÷7.5 and then treated in a partly aqueous solution with benzathine or a salt thereof, thus obtaining crystallization of a cephalosporin of formula (V) in which the carboxyl is salified by the benzathine, this salt being filtered off and washed with water.
US10/821,986 2003-12-02 2004-04-12 Process for preparing cephalosporins with salified intermediate Abandoned US20050119244A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/916,532 US7071329B2 (en) 2003-12-02 2004-08-12 Process for preparing cephalosporins with salified intermediate

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI2003A002354 2003-12-02
ITMI20032354 ITMI20032354A1 (en) 2003-12-02 2003-12-02 PROCEDURE FOR THE PREPARATION OF CEPHALOSPORINE WITH HEALED INTERMEDIATE.
ITMI20040233 ITMI20040233A1 (en) 2004-02-12 2004-02-12 PROCEDURE FOR THE PREPARATION OF Cephalosporins With Salified Intermediate
ITMI2004A000233 2004-02-12

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/916,532 Continuation US7071329B2 (en) 2003-12-02 2004-08-12 Process for preparing cephalosporins with salified intermediate
US10/916,532 Continuation-In-Part US7071329B2 (en) 2003-12-02 2004-08-12 Process for preparing cephalosporins with salified intermediate

Publications (1)

Publication Number Publication Date
US20050119244A1 true US20050119244A1 (en) 2005-06-02

Family

ID=34621688

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/821,986 Abandoned US20050119244A1 (en) 2003-12-02 2004-04-12 Process for preparing cephalosporins with salified intermediate
US10/916,532 Expired - Fee Related US7071329B2 (en) 2003-12-02 2004-08-12 Process for preparing cephalosporins with salified intermediate

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/916,532 Expired - Fee Related US7071329B2 (en) 2003-12-02 2004-08-12 Process for preparing cephalosporins with salified intermediate

Country Status (1)

Country Link
US (2) US20050119244A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080070A1 (en) * 2003-08-22 2005-04-14 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of cephalosporin antibiotic
US20060094872A1 (en) * 2003-08-22 2006-05-04 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of cephalosporin antibiotic
US20060135500A1 (en) * 2004-11-30 2006-06-22 Astellas Pharma Inc. Novel oral pharmaceutical suspension of cefdinir crystal
US20080207912A1 (en) * 2002-10-29 2008-08-28 Lupin Limited Method for manufacture of ceftiofur
US20080221076A1 (en) * 2005-10-12 2008-09-11 Orchid Chemicals And Pharmaceuticals Limited Crystalline Sodium Salt of Cephalosporin Antibiotic
US20110059933A1 (en) * 2005-10-12 2011-03-10 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
US20110136777A1 (en) * 2008-08-22 2011-06-09 Orchid Chemicals And Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
CN102603772A (en) * 2012-03-08 2012-07-25 哈药集团制药总厂 Method for preparing sterile cefmenoxime hydrochloride compound
CN102617605A (en) * 2012-02-29 2012-08-01 石药集团中诺药业（石家庄）有限公司 Ceftriaxone sodium compound and preparation method thereof
CN102718779A (en) * 2012-05-25 2012-10-10 深圳致君制药有限公司 Ceftizoxime sodium for injection and preparation method thereof as well as synthetic method for ceftizoxime sodium serving as crude drug
CN102875575A (en) * 2012-10-22 2013-01-16 海南合瑞制药股份有限公司 Cefodizime sodium compound and preparation thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20022076A1 (en) * 2002-10-01 2004-04-02 Antibioticos Spa INTERMEDIATE SALTS OF CEFDINIR.
US7098329B2 (en) * 2003-06-19 2006-08-29 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of a cephalosporin antibiotic
US20050059821A1 (en) * 2003-09-17 2005-03-17 Debashish Datta Method for manufacture of ceftriaxone sodium
US20050059820A1 (en) * 2003-09-17 2005-03-17 Debashish Datta Method for manufacture of ceftriaxone sodium
ITMI20042139A1 (en) * 2004-11-08 2005-02-08 Acs Dobfar Spa PROCEDURE FOR THE PRODUCTION OF CEFEPIME AND CEFAPOSPORINE ANALOGHE
WO2008047376A1 (en) * 2006-10-16 2008-04-24 Orchid Chemicals & Pharmaceuticals Limited An improved process for the preparation of cephalosporin antibiotic
CN101245078B (en) * 2007-03-19 2010-05-26 齐鲁动物保健品有限公司 Benzathine salt of ceftiofur, preparation method and application thereof
CN102885820A (en) * 2011-07-20 2013-01-23 洛阳惠中兽药有限公司 Medicinal composition containing ceftiofur bisbenzylethylenediamine
CN102584854A (en) * 2012-02-02 2012-07-18 瑞阳制药有限公司 Preparation technology of anhydrous crystal of cefotaxime sodium
CN104892636B (en) * 2015-05-21 2017-06-16 天津大学 A kind of method for preparing CTX sodium crystal
CN109096305A (en) * 2017-06-20 2018-12-28 刘兆娟 A kind of 1/4 water cefotaxime sodium compound
CN110396101B (en) * 2018-12-03 2021-01-22 广东金城金素制药有限公司 New indication of pharmaceutical preparation of troxofen ceftriaxone sodium for treating bacterial endometritis
CN110684038B (en) * 2019-05-05 2021-06-08 广东金城金素制药有限公司 Pharmaceutical preparation of compound of trissofene ceftriaxone sodium and new indication for treating pelvic inflammation
CN111647006B (en) * 2020-04-25 2021-06-08 广东金城金素制药有限公司 Cefotaxime sodium pharmaceutical preparation and treatment of salmonella infection indications including typhoid fever and paratyphoid fever
CN115772179A (en) * 2022-12-09 2023-03-10 山东鑫泉医药有限公司 Recrystallization method of ceftiofur sodium

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458072A (en) * 1980-10-10 1984-07-03 Hoffmann-La Roche Inc. Acyl derivatives
US5583216A (en) * 1974-12-19 1996-12-10 Takeda Chemical Industries, Ltd. Methods for the manufacture of cephems
US5705496A (en) * 1994-03-24 1998-01-06 Smithkline Beecham Corporation Crystalline benzathine salt of cefonicid and its preparation
US6384215B1 (en) * 2001-06-07 2002-05-07 Orchid Chemicals & Pharmaceuticals Ltd. Preparation of new intermediates and their use in manufacturing of cephalosporin compounds
US6458949B1 (en) * 2000-08-14 2002-10-01 Aurobindo Pharma Limited Ceftiofur, its intermediate and a process for the preparation of the same
US6552186B2 (en) * 1999-04-15 2003-04-22 Biochemie Gesellschaft M.B.H. β-lactam production

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5498795A (en) 1978-01-13 1979-08-03 Takeda Chem Ind Ltd Cephalosporin derivative and its preparation
FI67385C (en) 1979-11-21 1985-03-11 Hoffmann La Roche PROCEDURE FOR FRAMSTATION OF AV (6R 7R) -7- (2- (2-AMINO-4-THIAZOLYL) -2- (Z-METHOXYIMINO) ACETAMIDO) -3-CEFEM-4-CARBOXYL SYRATER DERIVATIVES
US20050059820A1 (en) * 2003-09-17 2005-03-17 Debashish Datta Method for manufacture of ceftriaxone sodium

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583216A (en) * 1974-12-19 1996-12-10 Takeda Chemical Industries, Ltd. Methods for the manufacture of cephems
US4458072A (en) * 1980-10-10 1984-07-03 Hoffmann-La Roche Inc. Acyl derivatives
US5705496A (en) * 1994-03-24 1998-01-06 Smithkline Beecham Corporation Crystalline benzathine salt of cefonicid and its preparation
US6552186B2 (en) * 1999-04-15 2003-04-22 Biochemie Gesellschaft M.B.H. β-lactam production
US6458949B1 (en) * 2000-08-14 2002-10-01 Aurobindo Pharma Limited Ceftiofur, its intermediate and a process for the preparation of the same
US6384215B1 (en) * 2001-06-07 2002-05-07 Orchid Chemicals & Pharmaceuticals Ltd. Preparation of new intermediates and their use in manufacturing of cephalosporin compounds

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080207912A1 (en) * 2002-10-29 2008-08-28 Lupin Limited Method for manufacture of ceftiofur
US20050080070A1 (en) * 2003-08-22 2005-04-14 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of cephalosporin antibiotic
US20060058281A1 (en) * 2003-08-22 2006-03-16 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of cephalosporin antibiotic
US20060094872A1 (en) * 2003-08-22 2006-05-04 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of cephalosporin antibiotic
US7339055B2 (en) * 2003-08-22 2008-03-04 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of cephalosporin antibiotic
US7345169B2 (en) * 2003-08-22 2008-03-18 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of cephalosporin antibiotic
US20060135500A1 (en) * 2004-11-30 2006-06-22 Astellas Pharma Inc. Novel oral pharmaceutical suspension of cefdinir crystal
US20070021402A1 (en) * 2004-11-30 2007-01-25 Astellas Pharma Inc. Novel Oral Pharmaceutical Suspension of Cefdinir Crystal
US7307072B2 (en) 2004-11-30 2007-12-11 Astellas Pharma Inc. Oral pharmaceutical suspension of Cefdinir crystal
US7351419B2 (en) 2004-11-30 2008-04-01 Astellas Pharma Inc. Oral pharmaceutical suspension of Cefdinir crystal
US20080221076A1 (en) * 2005-10-12 2008-09-11 Orchid Chemicals And Pharmaceuticals Limited Crystalline Sodium Salt of Cephalosporin Antibiotic
US20110059933A1 (en) * 2005-10-12 2011-03-10 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
US8212024B2 (en) * 2005-10-12 2012-07-03 Orchid Chemicals & Pharmaceuticals Ltd. Crystalline sodium salt of cephalosporin antibiotic
US8470809B2 (en) * 2005-10-12 2013-06-25 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
US20110136777A1 (en) * 2008-08-22 2011-06-09 Orchid Chemicals And Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
US8431562B2 (en) * 2008-08-22 2013-04-30 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
CN102617605A (en) * 2012-02-29 2012-08-01 石药集团中诺药业（石家庄）有限公司 Ceftriaxone sodium compound and preparation method thereof
CN102617605B (en) * 2012-02-29 2014-11-05 石药集团中诺药业（石家庄）有限公司 Ceftriaxone sodium compound and preparation method thereof
CN102603772A (en) * 2012-03-08 2012-07-25 哈药集团制药总厂 Method for preparing sterile cefmenoxime hydrochloride compound
CN102718779A (en) * 2012-05-25 2012-10-10 深圳致君制药有限公司 Ceftizoxime sodium for injection and preparation method thereof as well as synthetic method for ceftizoxime sodium serving as crude drug
CN102718779B (en) * 2012-05-25 2015-07-29 深圳致君制药有限公司 The synthetic method of ceftiaoxline sodium for injection and preparation method thereof, bulk drug ceftizoxime sodium
CN102875575A (en) * 2012-10-22 2013-01-16 海南合瑞制药股份有限公司 Cefodizime sodium compound and preparation thereof
CN102875575B (en) * 2012-10-22 2014-12-24 海南合瑞制药股份有限公司 Cefodizime sodium compound and preparation thereof

Also Published As

Publication number Publication date
US20050119478A1 (en) 2005-06-02
US7071329B2 (en) 2006-07-04

Similar Documents

Publication Publication Date Title
US20050119244A1 (en) Process for preparing cephalosporins with salified intermediate
EP0019345B1 (en) Process for the preparation of a (d-alpha-amino-(p-hydroxyphenyl)-acetamido) group containing cephalosporanic acid derivatives
US6458949B1 (en) Ceftiofur, its intermediate and a process for the preparation of the same
KR20080064990A (en) Process for the preparation of cefdinir
WO2005121154A1 (en) Process for the preparation of cefdinir
JP4856795B2 (en) Novel salts in the production of cephalosporin antibiotics.
US6825345B2 (en) Process for purification of a cephalosporin derivative
US7479556B2 (en) Process for producing Cefepime and cephalosporin analogues
CN107201391B (en) Synthesis method of cefepime hydrochloride
KR100265191B1 (en) Process for the preparation of cephem prodrug esters
EP1618114A2 (en) Processes for the preparations of cefepime
JP2609039B2 (en) New production method of ceftriaxone
CN101245078B (en) Benzathine salt of ceftiofur, preparation method and application thereof
US5034522A (en) Method for the production of 3-methyl cephem derivatives
KR20050035178A (en) A process for the preparation of cefixime via alkyl-or aryl-sulfonates
US4304909A (en) Process for producing 7-(D(-)-α-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-α-(4-hydroxyphenyl)acetamido)-3-(5-(1-methyl-1,2,3,4-tetrazolyl)thiomethyl)-.DELTA.3 -cephem-4-carboxylic acid and a pharmaceutically acceptable salt thereof
JP4223408B2 (en) Method for producing 2,6-dihalopurine
JPS5934199B2 (en) Bis-trimethylsilylcefamandole and its manufacturing method
EP0341991A2 (en) Method for recovery of antibiotics from mother liquors and novel pharmaceutically-acceptable salts thereof
US7847093B2 (en) Processes for the preparations of cefepime
US20040002601A1 (en) Method for producing cephalosporins
JPH0251433B2 (en)
JPS6019914B2 (en) Method for producing cephalosporanic acid compounds
JPH064640B2 (en) Process for producing 7-amino-3- (N-containing heterocyclic-substituted methyl) -3-cefm-4-carboxylate or salts thereof
NO160210B (en) N-TRIMETHYLSILYLOXYCARBONYL-6-AMINOPENICILLIN INTERMEDIATE FOR THE PREPARATION OF A PENICILLIN.

Legal Events

Date Code Title Description
AS Assignment

Owner name: ACS DOBFAR S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MONGUZZI, RICCARDO;MANCA, ANTONIO;MARSILI, LEONARDO;AND OTHERS;REEL/FRAME:015205/0355

Effective date: 20040310

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION